Table 3.
Associations Between Respiratory Symptoms, Lung Function Test, and Post–Severe Acute Respiratory Syndrome Coronavirus 2 Interstitial Lung Abnormalities
| Characteristic | Entire Cohort (N = 99) | Any Interstitial Abnormality Post–SARS-CoV-2 (n = 48) | No Interstitial Abnormality Post–SARS-CoV-2 Detected (n = 51) | P Value |
|---|---|---|---|---|
| Respiratory symptoms, No. (%) | ||||
| Sputum | 12 (12.1) | 5 (10.4) | 7 (13.7) | .84 |
| Wheezing | 6 (6.1) | 3 (6.2) | 3 (5.9) | 1 |
| Dyspnea (MRC scale >2) | 12 (12.1) | 8 (16.7) | 4 (7.8) | .28 |
| Lung function measures | ||||
| FEV1, L, mean (SD) | 2.78 (0.71) | 2.74 (0.78) | 2.83 (0.64) | .55 |
| FVC, L, mean (SD) | 3.65 (0.85) | 3.58 (0.90) | 3.73 (0.82) | .28 |
| FEV1/FVC, mean (SD) | 0.76 (0.08) | 0.77 (0.09) | 0.76 (0.07) | .56 |
| Mean decline in FEV1, mL, mean (SD) | 38.97 (41.67) | 39.47 (45.50) | 38.92 (38.61) | .95 |
| Mean decline in FVC, mL, mean (SD) | 63.58 (56.51) | 66.05 (68.36) | 62.59 (57.65) | .79 |
| DLCO, mmol/min/kPa, mean (SD) | 7.73 (2.03) | 7.18 (2.16) | 8.24 (1.76) | .01 |
| DLCO predicted, %, mean (SD) | 87.75 (16.56) | 82.98 (18.02) | 92.98 (13.20) | <.01 |
| TLC, L, mean (SD) | 5.52 (1.07) | 5.41 (1.09) | 5.62 (1.06) | .34 |
| TLC predicted, %, mean (SD) | 90.17 (10.72) | 87.02 (10.16) | 93.20 (10.47) | <.01 |
Abbreviations: DLCO, diffusing capacity of the lungs; FEV1, forced expiratory volume in first second; FVC, forced vital capacity; MRC, Medical Research Council; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation; TLC, total lung capacity. Significant p-values (<0.05) are in bold.